Trial Condition(s):

Hepatocellular Cancer

HCC patient preferences in Japan

Bayer Identifier:

18234

ClinicalTrials.gov Identifier:

NCT02616692

EudraCT Number:

Not Available

Study Completed

Trial Purpose

This non-interventional cross-sectional online survey will evaluate preferences among patients with self-reported HCC. The survey will ask patients to express their preferences regarding descriptions of HCC treatments, which will include sorafenib (which will be described as ‘oral anti-cancer therapy’), repeated transarterial chemoembolization (TACE), and hepatic arterial infusion chemotherapy (HAIC). Please note that all interventions that patients may have received before completing this online survey were given regardless of their participation in this survey. Questions also include asking patients to rank various treatment characteristics (e.g., mechanism of action, risk of adverse effects, etc.) relative to each other. The ultimate goal is to better understand patient perceptions of these treatments and to provide evidence to help in patients’ and physicians’ treatment decision-making in HCC.

Inclusion Criteria
The following eligibility criteria will be used:
 -  Have a diagnosis of HCC
 -  Are > 20 years of age 
 -  Reside in Japan 
 -  Are able to read and understand Japanese to provide informed consent and complete the survey instrument
Exclusion Criteria
None are currently considered

Trial Summary

Enrollment Goal
120
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Nexavar (Sorafenib, BAY43-9006)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Japan

Status
Completed
 

Trial Design